Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Front-Line Bevacizumab plus Chemotherapy with or without Maintenance Therapy for Metastatic Breast Cancer: An Observational Study by the Hellenic Oncology Research Group.
Kokkali S, Saloustros E, Stefanou D, Makrantonakis P, Kentepozidis N, Boukovinas I, Xenidis N, Katsaounis P, Ardavanis A, Ziras N, Christopoulou A, Rigas G, Kalbakis K, Vardakis N, Emmanouilides C, Athanasiadis I, Anagnostopoulos A, Hatzidaki D, Prinarakis E, Simopoulou F, Kotsakis A, Georgoulias V. Kokkali S, et al. Among authors: vardakis n. Curr Oncol. 2022 Feb 17;29(2):1237-1251. doi: 10.3390/curroncol29020105. Curr Oncol. 2022. PMID: 35200604 Free PMC article.
Gemcitabine plus oxaliplatin (GEMOX) in pretreated patients with advanced ovarian cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Kalykaki A, Papakotoulas P, Tsousis S, Boukovinas I, Kalbakis K, Vamvakas L, Kotsakis A, Vardakis N, Papadopoulou P, Georgoulias V, Mavroudis D; Hellenic Oncology Research Group. Kalykaki A, et al. Among authors: vardakis n. Anticancer Res. 2008 Jan-Feb;28(1B):495-500. Anticancer Res. 2008. PMID: 18383891 Free article. Clinical Trial.
Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer.
Kontopodis E, Kentepozidis N, Christophyllakis Ch, Boukovinas I, Kalykaki A, Kalbakis K, Vamvakas L, Agelaki S, Kotsakis A, Vardakis N, Georgoulias V, Mavroudis D. Kontopodis E, et al. Among authors: vardakis n. Cancer Chemother Pharmacol. 2015 Jan;75(1):153-60. doi: 10.1007/s00280-014-2628-0. Epub 2014 Nov 15. Cancer Chemother Pharmacol. 2015. PMID: 25398698 Clinical Trial.
Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase II study.
Kakolyris S, Ziras N, Vamvakas L, Varthalitis J, Papakotoulas P, Syrigos K, Vardakis N, Kalykaki A, Amarantidis K, Georgoulias V. Kakolyris S, et al. Among authors: vardakis n. Lung Cancer. 2006 Dec;54(3):347-52. doi: 10.1016/j.lungcan.2006.09.001. Epub 2006 Oct 9. Lung Cancer. 2006. PMID: 17030075 Clinical Trial.
Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer.
Xenidis N, Vardakis N, Varthalitis I, Giassas S, Kontopodis E, Ziras N, Gioulbasanis I, Samonis G, Kalbakis K, Georgoulias V. Xenidis N, et al. Among authors: vardakis n. Cancer Chemother Pharmacol. 2011 Jul;68(1):63-8. doi: 10.1007/s00280-010-1427-5. Epub 2010 Sep 10. Cancer Chemother Pharmacol. 2011. PMID: 20830475 Clinical Trial.
74 results